ArticleEuropean journal of nuclear medicine and molecular imaging2026
Superior correlation with clinical activity and unique detection patterns: a prospective study of FAPI versus FDG-PET in polymyalgia rheumatica and giant cell arteritis.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo perform a prospective comparative study of the novel FAPI-PET/CT with the established FDG-PET/CT for identifying characteristic inflammatory patterns in patients with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA).
methodsIn this prospective study, 78 patients (27 FAPI-PET, 51 FDG-PET) with PMR/GCA were enrolled using the 2012 EULAR/ACR criteria for PMR and the 2022 ACR/EULAR criteria for GCA, with diagnosis confirmed after a median 9.2-month follow-up. All underwent clinical and laboratory evaluation plus PET/CT imaging before any immunosuppressive treatment. The FAPI-PET Visual Index was derived by summing visual scores (0–3) across involved sites. Imaging findings were correlated with the PMR-AS and clinical outcomes.
resultsPure PMR accounted for 83.3% of the cohort. In PMR, FAPI-PET showed superior sensitivity in the shoulder girdle (91.3% vs. 66.7%, P = 0.02) and higher uptake intensity (SUVmax 9.5 vs. 5.6, P < 0.01) versus FDG-PET, which showed higher detection at sites like the ischial tuberosities. Crucially, the FAPI-PET Visual Index correlated strongly with PMR-AS (R = 0.751, P = 0.0002), significantly outperforming FDG-PET (R = 0.312, P = 0.0603). In the smaller GCA subgroup, FDG-PET appeared more sensitive for vascular involvement.
conclusionFAPI-PET demonstrates a distinct imaging profile and shows a superior correlation with clinical disease activity in PMR compared to FDG-PET in this comparative study. In the small subgroup of patients with GCA, FDG-PET appeared more sensitive for vascular involvement, but these findings require confirmation in larger studies. FAPI-PET shows promise as an imaging biomarker of active PMR, potentially improving diagnosis and phenotypic stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.